Retrieve available abstracts of 103 articles: HTML format
Single Articles
July 2025
AIZER AA, Tanguturi SK, Shi DD, Catalano PJ, et al Stereotactic Radiosurgery in Patients With Small Cell Lung Cancer and 1-10 Brain
Metastases: A Multi-Institutional, Phase II, Prospective Clinical Trial.
J Clin Oncol. 2025 Jul 11:JCO2500056. doi: 10.1200/JCO-25-00056. PubMedAbstract available
WU Y, Bi N Erratum: Mid-Treatment Positron Emission Tomography-Adaptive Radiotherapy in
Stage III Non-Small Cell Lung Cancer: Another Attempt Toward Personalized Care.
J Clin Oncol. 2025 Jul 10:JCO2501544. doi: 10.1200/JCO-25-01544. PubMed
SACHER AG, Miller WH Jr, Patel MR, Paz-Ares L, et al Single-Agent Divarasib in Patients With KRAS G12C-Positive Non-Small Cell Lung
Cancer: Long-Term Follow-Up of a Phase I Study.
J Clin Oncol. 2025 Jul 9:JCO2500040. doi: 10.1200/JCO-25-00040. PubMedAbstract available
June 2025
STEUER CE, Hayashi H, Su WC, Nishio M, et al Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non-Small Cell Lung Cancer After
Platinum-Based Chemotherapy and Immunotherapy.
J Clin Oncol. 2025 Jun 24:JCO2402744. doi: 10.1200/JCO-24-02744. PubMedAbstract available
HE J, Tsuboi M, Weder W, Chen KN, et al Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small-Cell Lung Cancer.
J Clin Oncol. 2025 Jun 2:101200JCO2500883. doi: 10.1200/JCO-25-00883. PubMedAbstract available
PIOTROWSKA Z, Passaro A, Nguyen D, Ruiter G, et al Zipalertinib in Patients With Epidermal Growth Factor Receptor Exon 20
Insertion-Positive Non-Small Cell Lung Cancer Previously Treated With
Platinum-Based Chemotherapy With or Without Amivantamab.
J Clin Oncol. 2025 Jun 1:JCO2500763. doi: 10.1200/JCO-25-00763. PubMedAbstract available
May 2025
FELIP E, Altorki N, Zhou C, Vallieres E, et al Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected
Stage IB-IIIA Non-Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized,
Phase III Trial.
J Clin Oncol. 2025 May 30:JCO2401681. doi: 10.1200/JCO-24-01681. PubMedAbstract available
HUANG DD, Yang JC Erratum: Every Patient Is Unique and Deserves the Best: The Present and Future
Treatment Landscape of Uncommon Epidermal Growth Factor Receptor Mutations in
Non-Small Cell Lung Cancer.
J Clin Oncol. 2025 May 8:JCO2500997. doi: 10.1200/JCO-25-00997. PubMed
April 2025
DEREK DE-RUI H, Yang JC Every Patient Is Unique and Deserves the Best: The Present and Future Treatment
Landscape of Uncommon Epidermal Growth Factor Receptor Mutations in Non-Small
Cell Lung Cancer.
J Clin Oncol. 2025 Apr 25:JCO2500625. doi: 10.1200/JCO-25-00625. PubMed
SCHYTTE T, Knap MM, Kristiansen C, Appelt AL, et al Toxicity Within 6 Months of Heterogeneous Fluorodeoxyglucose-Guided Radiotherapy
Dose Escalation for Locally Advanced Non-Small Cell Lung Cancer in the
Scandinavian Randomized Phase III NARLAL2 Trial.
J Clin Oncol. 2025 Apr 18:JCO2401386. doi: 10.1200/JCO-24-01386. PubMedAbstract available
MIURA S, Tanaka H, Misumi T, Yoshioka H, et al Pragmatic Randomized Study of Afatinib Versus Chemotherapy for Patients With
Non-Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor
Mutations: ACHILLES/TORG1834.
J Clin Oncol. 2025 Apr 16:JCO2402007. doi: 10.1200/JCO-24-02007. PubMedAbstract available
PEROL M, Li W, Pennell NA, Liu G, et al Taletrectinib in ROS1+ Non-Small Cell Lung Cancer: TRUST.
J Clin Oncol. 2025 Apr 3:JCO2500275. doi: 10.1200/JCO-25-00275. PubMedAbstract available
March 2025
THAWANI R, Bestvina CM, Vokes EE, Juloori A, et al Rationale for Investigation of Neoadjuvant Chemoimmunotherapy Before
Chemoradiation in Unresectable Stage III Non-Small Cell Lung Cancer.
J Clin Oncol. 2025 Mar 27:JCO2402355. doi: 10.1200/JCO-24-02355. PubMed
WU Y, Bi N Mid-Treatment Positron Emission Tomography-Adaptive Radiotherapy in Stage III
Non-Small Cell Lung Cancer: Another Attempt Toward Personalized Care.
J Clin Oncol. 2025 Mar 21:JCO2402532. doi: 10.1200/JCO-24-02532. PubMed
KONG FS, Hu C, Bradley JD, Machtay M, et al Reply to: Mid-Treatment Positron Emission Tomography-Adaptive Radiotherapy in
Stage III Non-Small Cell Lung Cancer: Another Attempt Toward Personalized Care.
J Clin Oncol. 2025 Mar 21:JCO2500069. doi: 10.1200/JCO-25-00069. PubMed
KINDLER HL, Ismaila N, Bazhenova L, Chu Q, et al Treatment of Pleural Mesothelioma: ASCO Guideline Update.
J Clin Oncol. 2025;43:1006-1038. PubMedAbstract available
SUN L, Marmarelis ME, Aggarwal C Management of Patients With EGFR Exon 20-Mutant Advanced Non-Small Cell Lung
Cancer.
J Clin Oncol. 2025 Mar 7:JCO2402624. doi: 10.1200/JCO-24-02624. PubMedAbstract available
February 2025
OWEN DH, Ismaila N, Ahluwalia A, Feldman J, et al Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO
Living Guideline, Version 2024.3.
J Clin Oncol. 2025 Feb 27:JCO2402785. doi: 10.1200/JCO-24-02785. PubMedAbstract available
LEIGHL NB, Ismaila N, Durm G, Florez N, et al Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO
Living Guideline, Version 2024.3.
J Clin Oncol. 2025 Feb 27:JCO2402786. doi: 10.1200/JCO-24-02786. PubMedAbstract available
GAUTSCHI O, Park K, Solomon BJ, Tomasini P, et al Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancer: Final Safety and
Efficacy, Including Overall Survival, From the LIBRETTO-001 Phase I/II Trial.
J Clin Oncol. 2025 Feb 21:JCO2402076. doi: 10.1200/JCO-24-02076. PubMedAbstract available
PIOTROWSKA Z Making Progress Along the Challenging Road of Drug Development for Patients With
EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer.
J Clin Oncol. 2025 Feb 5:JCO2402656. doi: 10.1200/JCO-24-02656. PubMed
January 2025
JANNE PA, Wang BC, Cho BC, Zhao J, et al First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR
Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer in the Phase III
EXCLAIM-2 Trial.
J Clin Oncol. 2025 Jan 29:JCO2401269. doi: 10.1200/JCO-24-01269. PubMedAbstract available
REMON J, Bortolot M, Bironzo P, Cortiula F, et al De-Escalation Strategies With Immune Checkpoint Blockers in Non-Small Cell Lung
Cancer: Do We Already Have Enough Evidence?
J Clin Oncol. 2025 Jan 21:JCO2402347. doi: 10.1200/JCO-24-02347. PubMedAbstract available
WERR L, Bartenhagen C, Rosswog C, Cartolano M, et al TERT Expression and Clinical Outcome in Pulmonary Carcinoids.
J Clin Oncol. 2025;43:214-225. PubMedAbstract available
AWAD MM, Forde PM, Girard N, Spicer J, et al Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung
Cancer.
J Clin Oncol. 2025 Jan 8:JCO2402239. doi: 10.1200/JCO-24-02239. PubMedAbstract available
PARK CJ, Lee ATM, Ou SI ALK Tyrosine Kinase Inhibitors Induced Weight Gain: More Refined Definition of
Weight Gain, Glucagon-Like Peptide-1 Agonist Treatment, and Therapeutic Drug
Monitoring of ALK+ Non-Small Cell Lung Cancer?
J Clin Oncol. 2025 Jan 7:JCO2402514. doi: 10.1200/JCO-24-02514. PubMed
SANDS J, Ahn MJ, Lisberg A, Cho BC, et al Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With
Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study.
J Clin Oncol. 2025 Jan 6:JCO2401349. doi: 10.1200/JCO-24-01349. PubMedAbstract available
December 2024
Erratum: Systemic Therapy for Small Cell Lung Cancer: ASCO Guideline Rapid
Recommendation Update.
J Clin Oncol. 2024 Dec 20:JCO2402719. doi: 10.1200/JCO-24-02719. PubMed
LUO LY, Xue W, Qumseya A, Vasquez JC, et al Whole Lung Irradiation in Rhabdomyosarcoma With Lung Metastases: A Report From
the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
J Clin Oncol. 2024;42:4263-4270. PubMedAbstract available
SIKKEMA BJ, Baart SJ, Paats MS, Smit EF, et al Body Weight Gain Associated With Alectinib in Patients With ALK+ Non-Small Cell
Lung Cancer: Pooled Analysis of Individual Patient Data From Four Prospective
Clinical Trials.
J Clin Oncol. 2024 Dec 11:JCO2401579. doi: 10.1200/JCO-24-01579. PubMedAbstract available
November 2024
KALEMKERIAN GP, Khurshid H, Ismaila N Systemic Therapy for Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation
Update.
J Clin Oncol. 2024 Nov 20:JCO2402245. doi: 10.1200/JCO-24-02245. PubMedAbstract available
NOGUCHI M, Shindo Y, Wakabayashi K, Koide Y, et al Significance of Up-Front Stereotactic Radiosurgery for Non-Small Cell Lung Cancer
Patients With Brain Metastases in the Era of New Generation Tyrosine Kinase
Inhibitors.
J Clin Oncol. 2024 Nov 15:JCO2401876. doi: 10.1200/JCO-24-01876. PubMed
RUSTHOVEN CG, Miao E, Boe LA, Pike LRG, et al Reply to: Significance of Up-Front Stereotactic Radiosurgery for Non-Small Cell
Lung Cancer Patients With Brain Metastases in the Era of New Generation Tyrosine
Kinase Inhibitors.
J Clin Oncol. 2024 Nov 15:JCO2402129. doi: 10.1200/JCO-24-02129. PubMed
Erratum: Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor
Resistance in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.
J Clin Oncol. 2024 Nov 12:JCO2402413. doi: 10.1200/JCO-24-02413. PubMed
BAZHENOVA L, Ismaila N, Abu Rous F, Alluri K, et al Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO
Living Guideline, Version 2024.2.
J Clin Oncol. 2024 Nov 12:JCO2402133. doi: 10.1200/JCO-24-02133. PubMedAbstract available
October 2024
LEIGHL NB, Akamatsu H, Lim SM, Cheng Y, et al Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib,
in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung
Cancer: Primary Results From the Phase III PALOMA-3 Study.
J Clin Oncol. 2024;42:3593-3605. PubMedAbstract available
KENMOTSU H Combination of Osimertinib and Vascular Endothelial Growth Factor Receptor
Inhibitors for EGFR-Mutated Non-Small Cell Lung Cancer: Old or New Regimen?
J Clin Oncol. 2024 Oct 11:JCO2401921. doi: 10.1200/JCO-24-01921. PubMed
LE X, Patel JD, Shum E, Baik C, et al A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and
Without Ramucirumab in Tyrosine Kinase Inhibitor-Naive EGFR-Mutant Metastatic
Non-Small Cell Lung Cancer (RAMOSE trial).
J Clin Oncol. 2024 Oct 8:JCO2400533. doi: 10.1200/JCO.24.00533. PubMedAbstract available
SUN H, Li M, Huang W, Zhang J, et al Thoracic Radiotherapy Improves the Survival in Patients With EGFR-Mutated
Oligo-Organ Metastatic Non-Small Cell Lung Cancer Treated With Epidermal Growth
Factor Receptor-Tyrosine Kinase Inhibitors: A Multicenter, Randomized,
Controlled, Phase III Tria
J Clin Oncol. 2024 Oct 7:JCO2302075. doi: 10.1200/JCO.23.02075. PubMedAbstract available
OWEN D, Chapman CH Can We Offset Local Recurrence in Locally Advanced Non-Small Cell Lung Cancer?
The Merry-Go-Round of Radiation Dose Escalation and Stubborn Outcomes.
J Clin Oncol. 2024 Oct 4:JCO2401448. doi: 10.1200/JCO-24-01448. PubMedAbstract available
KONG FS, Hu C, Pryma DA, Duan F, et al Primary Results of NRG-RTOG1106/ECOG-ACRIN 6697: A Randomized Phase II Trial of
Individualized Adaptive (chemo)Radiotherapy Using Midtreatment
(18)F-Fluorodeoxyglucose Position Emission Tomography/Computed Tomography in
Stage III Non-Small Cell Lung C
J Clin Oncol. 2024 Oct 4:JCO2400022. doi: 10.1200/JCO.24.00022. PubMedAbstract available
COOPER AJ, Riely GJ Can We Find a Place for Trophoblast Cell Surface Antigen 2-Targeted Antibody-Drug
Conjugates in Lung Cancer?
J Clin Oncol. 2024 Oct 1:JCO2401900. doi: 10.1200/JCO-24-01900. PubMed
September 2024
Erratum: Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic
Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II
DESTINY-Lung02 Trial.
J Clin Oncol. 2024 Sep 13:JCO2401883. doi: 10.1200/JCO-24-01883. PubMed
AHN MJ, Tanaka K, Paz-Ares L, Cornelissen R, et al Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or
Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III
TROPION-Lung01 Study.
J Clin Oncol. 2024 Sep 9:JCO2401544. doi: 10.1200/JCO-24-01544. PubMedAbstract available
LOVLY CM New Benchmark for Targeted Therapies in Lung Cancer: Median Progression-Free
Survival for Lorlatinib in Advanced ALK+ Non-Small Cell Lung Cancer Surpasses 5
years.
J Clin Oncol. 2024 Sep 4:JCO2401147. doi: 10.1200/JCO.24.01147. PubMed
CAMIDGE DR, Bar J, Horinouchi H, Goldman J, et al Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met
Protein-Overexpressing Advanced Nonsquamous EGFR-Wildtype Non-Small Cell Lung
Cancer in the Phase II LUMINOSITY Trial.
J Clin Oncol. 2024;42:3000-3011. PubMedAbstract available
August 2024
DOWLATI A, Hummel HD, Champiat S, Olmedo ME, et al Sustained Clinical Benefit and Intracranial Activity of Tarlatamab in Previously
Treated Small Cell Lung Cancer: DeLLphi-300 Trial Update.
J Clin Oncol. 2024 Aug 29:JCO2400553. doi: 10.1200/JCO.24.00553. PubMedAbstract available
KETPUEAK T, Tan DSW, Popat S Immunotherapy in EGFR-Mutant Non-Small Cell Lung Cancer: End of the Road or the
First Chapter?
J Clin Oncol. 2024 Aug 26:JCO2400829. doi: 10.1200/JCO.24.00829. PubMed
YANG JC, Lee DH, Lee JS, Fan Y, et al Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without
Pembrolizumab for Tyrosine Kinase Inhibitor?Resistant, EGFR-Mutant, Metastatic
Nonsquamous Non-Small Cell Lung Cancer.
J Clin Oncol. 2024 Aug 22:JCO2302747. doi: 10.1200/JCO.23.02747. PubMedAbstract available
GREER JA, Post KE, Chabria R, Aribindi S, et al Randomized Controlled Trial of a Nurse-Led Brief Behavioral Intervention for
Dyspnea in Patients With Advanced Lung Cancer.
J Clin Oncol. 2024 Aug 1:JCO2400048. doi: 10.1200/JCO.24.00048. PubMedAbstract available
July 2024
YANG JJ, Zhang Y, Wu L, Hu J, et al Vebreltinib for Advanced Non-Small Cell Lung Cancer Harboring c-Met Exon 14
Skipping Mutation: A Multicenter, Single-Arm, Phase II KUNPENG Study.
J Clin Oncol. 2024 Jul 26:JCO2302363. doi: 10.1200/JCO.23.02363. PubMedAbstract available
PIKE LRG, Miao E, Boe LA, Patil T, et al Tyrosine Kinase Inhibitors With and Without Up-Front Stereotactic Radiosurgery
for Brain Metastases From EGFR and ALK Oncogene-Driven Non-Small Cell Lung Cancer
(TURBO-NSCLC).
J Clin Oncol. 2024 Jul 24:JCO2302668. doi: 10.1200/JCO.23.02668. PubMedAbstract available
DALY ME, Singh N, Ismaila N Management of Stage III Non-Small Cell Lung Cancer: ASCO Rapid Recommendation
Update.
J Clin Oncol. 2024 Jul 23:JCO2401324. doi: 10.1200/JCO-24-01324. PubMedAbstract available
DZIADZIUSZKO R, Rzyman W At the Crossroads of Local and Systemic Treatment of Operable Non-Small Cell Lung
Cancer.
J Clin Oncol. 2024 Jul 23:JCO2401099. doi: 10.1200/JCO.24.01099. PubMed
ELKRIEF A, Montesion M, Sivakumar S, Hale C, et al Intratumoral Escherichia Is Associated With Improved Survival to Single-Agent
Immune Checkpoint Inhibition in Patients With Advanced Non-Small-Cell Lung
Cancer.
J Clin Oncol. 2024 Jul 22:JCO2301488. doi: 10.1200/JCO.23.01488. PubMedAbstract available
KAPADIA P, Zimolzak AJ, Upadhyay DK, Korukonda S, et al Development and Implementation of a Digital Quality Measure of Emergency Cancer
Diagnosis.
J Clin Oncol. 2024;42:2506-2515. PubMedAbstract available
BLAKELY CM, Urisman A, Gubens MA, Mulvey CK, et al Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor
Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter Study.
J Clin Oncol. 2024 Jul 19:JCO2400071. doi: 10.1200/JCO.24.00071. PubMedAbstract available
PEROL M TROP2-Directed Antibody-Drug Conjugates in Advanced Non-Small Cell Lung Cancer: A
Fading Hope?
J Clin Oncol. 2024 Jul 10:JCO2401043. doi: 10.1200/JCO.24.01043. PubMed
June 2024
WALIANY S, Lin JJ Taletrectinib: TRUST in the Continued Evolution of Treatments for ROS1
Fusion-Positive Lung Cancer.
J Clin Oncol. 2024 Jun 28:JCO2401062. doi: 10.1200/JCO.24.01062. PubMed
Erratum: Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and
Chemotherapy in Patients With EGFR- or ALK-Mutated Non-Small-Cell Lung Cancer
(ATTLAS, KCSG-LU19-04).
J Clin Oncol. 2024 Jun 17:JCO2401092. doi: 10.1200/JCO.24.01092. PubMed
YU Y, Miao E, Pike LRG Improved CNS Control With the Addition of Chemotherapy to Osimertinib: A Devil's
Bargain?
J Clin Oncol. 2024;42:2107-2108. PubMed
PARK S, Baldry R, Jung HA, Sun JM, et al Phase II Efficacy and Safety of 80 mg Osimertinib in Patients With Leptomeningeal
Metastases Associated With Epidermal Growth Factor Receptor Mutation-Positive
Non-Small Cell Lung Cancer (BLOSSOM).
J Clin Oncol. 2024 Jun 3:JCO2400708. doi: 10.1200/JCO.24.00708. PubMedAbstract available
PEROL M, Solomon BJ, Goto K, Park K, et al CNS Protective Effect of Selpercatinib in First-Line RET Fusion-Positive Advanced
Non-Small Cell Lung Cancer.
J Clin Oncol. 2024 Jun 3:JCO2400724. doi: 10.1200/JCO.24.00724. PubMedAbstract available
LI W, Xiong A, Yang N, Fan H, et al Efficacy and Safety of Taletrectinib in Chinese Patients With ROS1+ Non-Small
Cell Lung Cancer: The Phase II TRUST-I Study.
J Clin Oncol. 2024 Jun 1:JCO2400731. doi: 10.1200/JCO.24.00731. PubMedAbstract available
May 2024
SOLOMON BJ, Liu G, Felip E, Mok TSK, et al Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small
Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study.
J Clin Oncol. 2024 May 31:JCO2400581. doi: 10.1200/JCO.24.00581. PubMedAbstract available
PAZ-ARES LG, Juan-Vidal O, Mountzios GS, Felip E, et al Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or
Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III
EVOKE-01 Study.
J Clin Oncol. 2024 May 31:JCO2400733. doi: 10.1200/JCO.24.00733. PubMedAbstract available
OWEN DH, Ismaila N, Freeman-Daily J, Roof L, et al Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO
Living Guideline, Version 2024.1.
J Clin Oncol. 2024 May 30:JCO2400762. doi: 10.1200/JCO.24.00762. PubMedAbstract available
MO DC, Chen L, Wu Y, Huang JF, et al PD-L1 Expression and Its Prognostic Value in Different Tumor Specimens in
Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer.
J Clin Oncol. 2024 May 16:JCO2400230. doi: 10.1200/JCO.24.00230. PubMed
April 2024
SPIGEL DR, Dowlati A, Chen Y, Navarro A, et al RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal
Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer.
J Clin Oncol. 2024 Apr 22:JCO2302110. doi: 10.1200/JCO.23.02110. PubMedAbstract available
DAI W, Wang Y, Liao J, Wei X, et al Electronic Patient-Reported Outcome-Based Symptom Management Versus Usual Care
After Lung Cancer Surgery: Long-Term Results of a Multicenter, Randomized,
Controlled Trial.
J Clin Oncol. 2024 Apr 4:JCO2301854. doi: 10.1200/JCO.23.01854. PubMedAbstract available
March 2024
NEAL J, Pavlakis N, Kim SW, Goto Y, et al CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus
Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor
and Chemotherapy.
J Clin Oncol. 2024 Mar 29:JCO2302166. doi: 10.1200/JCO.23.02166. PubMedAbstract available
POTTER AL, Xu NN, Senthil P, Srinivasan D, et al Pack-Year Smoking History: An Inadequate and Biased Measure to Determine Lung
Cancer Screening Eligibility.
J Clin Oncol. 2024 Mar 27:JCO2301780. doi: 10.1200/JCO.23.01780. PubMedAbstract available
KATHURIA H, Wiener RS Toward Racial Equity in Lung Cancer Screening Eligibility.
J Clin Oncol. 2024 Mar 27:JCO2400351. doi: 10.1200/JCO.24.00351. PubMed
RODRIGUEZ GM, Popat R, Rosas LG, Patel MI, et al Racial and Ethnic Disparities in Intensity of Care at the End of Life for
Patients With Lung Cancer: A 13-Year Population-Based Study.
J Clin Oncol. 2024 Mar 13:JCO2301045. doi: 10.1200/JCO.23.01045. PubMedAbstract available
February 2024
HENICK BS, Herzberg BO, Concepcion-Crisol CP, Taylor AM, et al Controlled Chaos: Parsing Acquired Immunoresistance in Lung Cancer.
J Clin Oncol. 2024 Feb 29:JCO2302339. doi: 10.1200/JCO.23.02339. PubMed
JAIYESIMI IA, Leighl NB, Ismaila N, Alluri K, et al Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO
Living Guideline, Version 2023.3.
J Clin Oncol. 2024 Feb 28:JCO2302746. doi: 10.1200/JCO.23.02746. PubMedAbstract available
JAIYESIMI IA, Leighl NB, Ismaila N, Alluri K, et al Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO
Living Guideline, Version 2023.3.
J Clin Oncol. 2024 Feb 28:JCO2302744. doi: 10.1200/JCO.23.02744. PubMedAbstract available
PIPER VALLILLO AJ, Viray H, Feldman J, Rangachari D, et al Management of Treatment Resistance in Patients With Advanced Epidermal Growth
Factor Receptor-Mutated Lung Cancer: Personalization, Parsimony, and Partnership.
J Clin Oncol. 2024 Feb 27:JCO2302417. doi: 10.1200/JCO.23.02417. PubMedAbstract available
REMON J, Besse B, Aix SP, Callejo A, et al Overall Survival From the EORTC LCG-163 APPLE Trial of Osimertinib Versus
Gefitinib Followed by Osimertinib in Advanced EGFR-Mutant Non-Small-Cell Lung
Cancer.
J Clin Oncol. 2024 Feb 7:JCO2301521. doi: 10.1200/JCO.23.01521. PubMedAbstract available
January 2024
MOK T, Nakagawa K, Park K, Ohe Y, et al Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated
Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal
Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate
722.
J Clin Oncol. 2024 Jan 22:JCO2301017. doi: 10.1200/JCO.23.01017. PubMedAbstract available
STINCHCOMBE TE, Wang X, Damman B, Mentlick J, et al Secondary Analysis of the Rate of Second Primary Lung Cancer From Cancer and
Leukemia Group B 140503 (Alliance) Trial of Lobar Versus Sublobar Resection for
T1aN0 Non-Small-Cell Lung Cancer.
J Clin Oncol. 2024 Jan 12:JCO2301306. doi: 10.1200/JCO.23.01306. PubMedAbstract available
RICCIUTI B, Lamberti G, Puchala SR, Mahadevan NR, et al Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade
in Non-Small-Cell Lung Cancer.
J Clin Oncol. 2024 Jan 11:JCO2300580. doi: 10.1200/JCO.23.00580. PubMedAbstract available
FENG YN, Xiao L, Xie GY Atezolizumab in Advanced Squamous Cell Carcinoma of the Penis.
J Clin Oncol. 2024;42:242-243. PubMed
MERIC-BERNSTAM F, Makker V, Oaknin A, Oh DY, et al Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing
Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial.
J Clin Oncol. 2024;42:47-58. PubMedAbstract available
December 2023
Erratum: Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic
Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II
DESTINY-Lung02 Trial.
J Clin Oncol. 2023 Dec 19:JCO2302574. doi: 10.1200/JCO.23.02574. PubMed
DE VIS JB, Cmelak AJ, Osmundson EC Chemoimmunotherapy for Untreated Lung Cancer Brain Metastases: Systemic Before
Local Therapy?
J Clin Oncol. 2023 Dec 11:JCO2302151. doi: 10.1200/JCO.23.02151. PubMed
LEHRER EJ, Trifiletti DM, Fadul CE, Brown PD, et al Chemoimmunotherapy for Untreated Lung Cancer Brain Metastases: A Reason for
Optimism While Avoiding Overreaching Interpretations.
J Clin Oncol. 2023 Dec 11:JCO2301876. doi: 10.1200/JCO.23.01876. PubMed
Erratum: Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients
With BRAF(V600)-Mutant Metastatic Non-Small-Cell Lung Cancer.
J Clin Oncol. 2023 Dec 5:JCO2302518. doi: 10.1200/JCO.23.02518. PubMed
JANNE PA, Planchard D, Kobayashi K, Cheng Y, et al CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth
Factor Receptor-Mutated Advanced Non-Small-Cell Lung Cancer.
J Clin Oncol. 2023 Dec 2:JCO2302219. doi: 10.1200/JCO.23.02219. PubMedAbstract available
TAN DSW, Felip E, de Castro G, Solomon BJ, et al Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus
Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1
Trial.
J Clin Oncol. 2023 Dec 1:JCO2300980. doi: 10.1200/JCO.23.00980. PubMedAbstract available
November 2023
UPRETY D, Remon J, Peters S First-Line Dual Immunotherapy, a Treatment Option in First-Line Metastatic
Non-Small-Cell Lung Cancer: Are We Ready to Use It?
J Clin Oncol. 2023 Nov 30:JCO2301524. doi: 10.1200/JCO.23.01524. PubMed
OHRI N, Jolly S, Cooper BT, Kabarriti R, et al Selective Personalized Radioimmunotherapy for Locally Advanced Non-Small-Cell
Lung Cancer Trial.
J Clin Oncol. 2023 Nov 21:JCO2300627. doi: 10.1200/JCO.23.00627. PubMedAbstract available
RUDIN CM, Liu SV, Soo RA, Lu S, et al SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in
Untreated Extensive-Stage Small-Cell Lung Cancer.
J Clin Oncol. 2023 Nov 17:JCO2301363. doi: 10.1200/JCO.23.01363. PubMedAbstract available
MONK BJ, Colombo N, Tewari KS, Dubot C, et al First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for
Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival
Results of KEYNOTE-826.
J Clin Oncol. 2023 Nov 1:JCO2300914. doi: 10.1200/JCO.23.00914. PubMedAbstract available
October 2023
PARK S, Kim TM, Han JY, Lee GW, et al A Phase 3, Randomized study of atezolizumab plus bevacizumab and chemotherapy in
patients with EGFR or ALK mutated in non-small cell lung cancer (ATTLAS,
KCSG-LU19-04).
J Clin Oncol. 2023 Oct 20:101200JCO2301891. doi: 10.1200/JCO.23.01891. PubMedAbstract available
HENDRIKS LEL, Remon J Speeding up Antibody-Drug Conjugate Development in Pretreated EGFR-Mutant
Non-Small-Cell Lung Cancer.
J Clin Oncol. 2023 Oct 12:JCO2301830. doi: 10.1200/JCO.23.01830. PubMed
KHURSHID H, Ismaila N, Bian J, Dabney R, et al Systemic Therapy for Small-Cell Lung Cancer: ASCO-Ontario Health (Cancer Care
Ontario) Guideline.
J Clin Oncol. 2023 Oct 11:JCO2301435. doi: 10.1200/JCO.23.01435. PubMedAbstract available
GARON EB, Lu S, Goto Y, De Marchi P, et al Canakinumab as Adjuvant Therapy in Patients With Completely Resected
Non-Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized
Clinical Trial.
J Clin Oncol. 2023 Oct 3:JCO2300910. doi: 10.1200/JCO.23.00910. PubMedAbstract available
September 2023
Erratum: Selpercatinib in Patients With RET Fusion-Positive Non-Small-Cell Lung
Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase
I/II Trial.
J Clin Oncol. 2023 Sep 13:JCO2301849. doi: 10.1200/JCO.23.01849. PubMed
GOTO K, Goto Y, Kubo T, Ninomiya K, et al Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell
Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial.
J Clin Oncol. 2023 Sep 11:JCO2301361. doi: 10.1200/JCO.23.01361. PubMedAbstract available
HOE HJ, Solomon BJ Optimizing Dosing of Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung
Cancer: A Reminder That More Is Not Always Better.
J Clin Oncol. 2023 Sep 11:JCO2301768. doi: 10.1200/JCO.23.01768. PubMed
YU HA, Goto Y, Hayashi H, Felip E, et al HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in
Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and
Platinum-Based Chemotherapy.
J Clin Oncol. 2023 Sep 10:JCO2301476. doi: 10.1200/JCO.23.01476. PubMedAbstract available
August 2023
VERGOTE I, Van Nieuwenhuysen E, O'Cearbhaill RE, Westermann A, et al Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab
in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV
205/GOG-3024/ENGOT-cx8 Study.
J Clin Oncol. 2023 Aug 31:JCO2300720. doi: 10.1200/JCO.23.00720. PubMedAbstract available